Clostridium difficile extracytoplasmic function σ factor σV regulates lysozyme resistance and is necessary for pathogenesis in the hamster model of infection

Infection and Immunity

Volumn 82, Issue 6, 2014, Pages 2345-2355

  Ho, Theresa D ^a   Williams, Kyle B ^a   Chen, Yan ^b   Helm, Richard F ^b   Popham, David L ^b   Ellermeier, Craig D ^a  

^a UNIVERSITY OF IOWA   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BACITRACIN; CLINDAMYCIN; COLISTIN; LYSOZYME; NISIN; PEPTIDOGLYCAN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; SIGMA FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM MUTANT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTION; CONTROLLED STUDY; DEACETYLATION; EXTRACYTOPLASMIC FUNCTION SIGMA FACTOR SIGMA V GENE; GENE EXPRESSION; HAMSTER MODEL; INNATE IMMUNITY; MICROARRAY ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULON; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HAMSTER; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; PSEUDOMEMBRANOUS COLITIS; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CRICETINAE; DISEASE MODELS, ANIMAL; DNA, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; MICROARRAY ANALYSIS; MICROBIAL SENSITIVITY TESTS; MURAMIDASE; SIGMA FACTOR; VIRULENCE;

EID: 84900409099     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01483-13     Document Type: Article

References (51)

1. Kyne L, Hamel MB, Polavaram R, Kelly CP. 2002. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34:346-353. http://dx.doi.org/10.1086/338260.
2. Bartlett JG. 1992. Antibiotic-associated diarrhea. Clin. Infect. Dis. 15: 573-581. http://dx.doi.org/10.1093/clind/15.4.573.
3. Kelly CP, LaMont JT. 1998. Clostridium difficile infection. Annu. Rev. Med. 49:375-390. http://dx.doi.org/10.1146/annurev.med.49.1.375.
4. Pépin J, Valiquette L, Alary M, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. 2004. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466-472. http://dx.doi.org/10.1503/cmaj.1041104.
5. McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. 2007. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin. Infect. Dis. 45:1141-1151. http://dx.doi.org/10.1086/522187.
6. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. 1989. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320: 204-210. http://dx.doi.org/10.1056/NEJM198901263200402.
7. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179. http://dx.doi.org/10.1038/nature07822.
8. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263. http://dx.doi.org/10.1128/CMR.18.2.247-263.2005.
9. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713. http://dx.doi.org/10.1038/nature09397.
10. Kuehne SA, Cartman ST, Minton NP. 2011. Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes 2:252-255. http://dx.doi.org/10.4161/gmic.2.4.16109.
11. Mani N, Dupuy B. 2001. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc. Natl. Acad. Sci. U. S. A. 98:5844-5849. http://dx.doi.org/10.1073/pnas.101126598.
12. Dineen SS, Villapakkam AC, Nordman JT, Sonenshein AL. 2007. Repression of Clostridium difficile toxin gene expression by CodY. Mol. Microbiol. 66:206-219. http://dx.doi.org/10.1111/j.1365-2958.2007.05906.x.
13. Antunes A, Martin-Verstraete I, Dupuy B. 2011. CcpA-mediated repression of Clostridium difficile toxin gene expression. Mol. Microbiol. 79: 882-899. http://dx.doi.org/10.1111/j.1365-2958.2010.07495.x.
14. Callewaert L, Michiels CW. 2010. Lysozymes in the animal kingdom. J. Biosci. 35:127-160. http://dx.doi.org/10.1007/s12038-010-0015-5.
15. Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, Meehl M, Cheung A, Götz F. 2007. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog. 3:e102. http://dx.doi.org/10.1371/journal.ppat.0030102.
16. Bera A, Herbert S, Jakob A, Vollmer W, Götz F. 2005. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan Oacetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol. Microbiol. 55:778-787. http://dx.doi.org/10.1111/j.1365-2958.2004.04446.x.
17. Aubry C, Goulard C, Nahori M-A, Cayet N, Decalf J, Sachse M, Boneca IG, Cossart P, Dussurget O. 2011. OatA, a peptidoglycan Oacetyltransferase involved in Listeria monocytogenes immune escape, is critical for virulence. J. Infect. Dis. 204:731-740. http://dx.doi.org/10.1093/infdis/jir396.
18. Boneca IG, Dussurget O, Cabanes D, Nahori M-A, Sousa S, Lecuit M, Psylinakis E, Bouriotis V, Hugot J-P, Giovannini M, Coyle A, Bertin J, Namane A, Rousselle J-C, Cayet N, Prévost M-C, Balloy V, Chignard M, Philpott DJ, Cossart P, Girardin SE. 2007. A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system. Proc. Natl. Acad. Sci. U. S. A. 104:997-1002. http://dx.doi.org/10.1073/pnas.0609672104.
19. Benachour A, Ladjouzi R, Le Jeune A, Hébert L, Thorpe S, Courtin P, Chapot-Chartier M-P, Prajsnar TK, Foster SJ, Mesnage S. 2012. The lysozyme-induced peptidoglycan N-acetylglucosamine deacetylase PgdA (EF1843) is required for Enterococcus faecalis virulence. J. Bacteriol. 194: 6066-6073. http://dx.doi.org/10.1128/JB.00981-12.
20. Fittipaldi N, Sekizaki T, Takamatsu D, de la Cruz Domínguez-Punaro M, Harel J, Bui NK, Vollmer W, Gottschalk M. 2008. Significant contribution of the pgdA gene to the virulence of Streptococcus suis. Mol. Microbiol. 70:1120-1135. http://dx.doi.org/10.1111/j.1365-2958.2008.06463.x.
21. Le Jeune A, Torelli R, Sanguinetti M, Giard J-C, Hartke A, Auffray Y, Benachour A. 2010. The extracytoplasmic function sigma factor SigV plays a key role in the original model of lysozyme resistance and virulence of Enterococcus faecalis. PLoS One 5:e9658. http://dx.doi.org/10.1371/journal.pone.0009658.
22. Laaberki M-H, Pfeffer J, Clarke AJ, Dworkin J. 2011. O-Acetylation of peptidoglycan is required for proper cell separation and S-layer anchoring in Bacillus anthracis. J. Biol. Chem. 286:5278-5288. http://dx.doi.org/10.1074/jbc.M110.183236.
23. Bernard E, Rolain T, Courtin P, Guillot A, Langella P, Hols P, Chapot-Chartier M-P. 2011. Characterization of O-acetylation of Nacetylglucosamine: a novel structural variation of bacterial peptidoglycan. J. Biol. Chem. 286:23950-23958. http://dx.doi.org/10.1074/jbc.M111.241414.
24. Vollmer W, Tomasz A. 2000. The pgdA gene encodes for a peptidoglycan N-acetylglucosamine deacetylase in Streptococcus pneumoniae. J. Biol. Chem. 275:20496-20501. http://dx.doi.org/10.1074/jbc.M910189199.
25. Psylinakis E, Boneca IG, Mavromatis K, Deli A, Hayhurst E, Foster SJ, Varum KM, Bouriotis V. 2005. Peptidoglycan N-acetylglucosamine deacetylases from Bacillus cereus, highly conserved proteins in Bacillus anthracis. J. Biol. Chem. 280:30856-30863. http://dx.doi.org/10.1074/jbc.M407426200.
26. Milani CJE, Aziz RK, Locke JB, Dahesh S, Nizet V, Buchanan JT. 2010. The novel polysaccharide deacetylase homologue Pdi contributes to virulence of the aquatic pathogen Streptococcus iniae. Microbiology 156:543-554. http://dx.doi.org/10.1099/mic.0.028365-0.
27. Kobayashi K, Sudiarta IP, Kodama T, Fukushima T, Ara K, Ozaki K, Sekiguchi J. 2012. Identification and characterization of a novel polysaccharide deacetylase C (PdaC) from Bacillus subtilis. J. Biol. Chem. 287: 9765-9776. http://dx.doi.org/10.1074/jbc.M111.329490.
28. Staroń A, Sofia HJ, Dietrich S, Ulrich LE, Liesegang H, Mascher T. 2009. The third pillar of bacterial signal transduction: classification of the extracytoplasmic function (ECF) sigma factor protein family. Mol. Microbiol. 74:557-581. http://dx.doi.org/10.1111/j.1365-2958.2009.06870.x.
29. Helmann JD. 2002. The extracytoplasmic function (ECF) sigma factors. Adv. Microb. Physiol. 46:47-110. http://dx.doi.org/10.1016/S0065-2911(02)46002-X.
30. Ho TD, Ellermeier CD. 2012. Extracytoplasmic function σ factor activation. Curr. Opin. Microbiol. 15:182-188. http://dx.doi.org/10.1016/j.mib.2012.01.001.
31. Ho TD, Ellermeier CD. 2011. PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function σ factors in Clostridium difficile. Infect. Immun. 79:3229-3238. http://dx.doi.org/10.1128/IAI.00019-11.
32. Ho TD, Hastie JL, Intile PJ, Ellermeier CD. 2011. The Bacillus subtilis extracytoplasmic function σ factor σ(V) is induced by lysozyme and provides resistance to lysozyme. J. Bacteriol. 193:6215-6222. http://dx.doi.org/10.1128/JB.05467-11.
33. Guariglia-Oropeza V, Helmann JD. 2011. Bacillus subtilis σ(V) confers lysozyme resistance by activation of two cell wall modification pathways, peptidoglycan O-acetylation and D-alanylation of teichoic acids. J. Bacteriol. 193:6223-6232. http://dx.doi.org/10.1128/JB.06023-11.
34. Hastie JL, Williams KB, Ellermeier CD. 2013. The activity of σV, an extracytoplasmic function σ factor of Bacillus subtilis, is controlled by a regulated proteolysis of the anti-σ factor RsiV. J. Bacteriol. 195:3135-3144. http://dx.doi.org/10.1128/JB.00292-13.
35. Varahan S, Iyer VS, Moore WT, Hancock LE. 2013. Eep confers lysozyme resistance to Enterococcus faecalis via the activation of the extracytoplasmic function sigma factor SigV. J. Bacteriol. 195:3125-3134. http://dx.doi.org/10.1128/JB.00291-13.
36. O'Connor JR, Lyras D, Farrow KA, Adams V, Powell DR, Hinds J, Cheung JK, Rood JI. 2006. Construction and analysis of chromosomal Clostridium difficile mutants. Mol. Microbiol. 61:1335-1351. http://dx.doi.org/10.1111/j.1365-2958.2006.05315.x.
37. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, Stabler R, Thomson NR, Roberts AP, Cerdeño-Tárraga AM, Wang H, Holden MTG, Wright A, Churcher C, Quail MA, Baker S, Bason N, Brooks K, Chillingworth T, Cronin A, Davis P, Dowd L, Fraser A, Feltwell T, Hance Z, Holroyd S, Jagels K, Moule S, Mungall K, Price C, Rabbinowitsch E, Sharp S, Simmonds M, Stevens K, Unwin L, Whithead S, Dupuy B, Dougan G, Barrell B, Parkhill J. 2006. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat. Genet. 38:779-786. http://dx.doi.org/10.1038/ng1830.
38. Wilson KH, Kennedy MJ, Fekety FR. 1982. Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J. Clin. Microbiol. 15:443-446.
39. Bouillaut L, Self WT, Sonenshein AL. 2013. Proline-dependent regulation of Clostridium difficile Stickland metabolism. J. Bacteriol. 195:844-854. http://dx.doi.org/10.1128/JB.01492-12.
40. Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP. 2010. The ClosTron: mutagenesis in Clostridium refined and streamlined. J. Microbiol. Methods 80:49-55. doi.org/10.1016/j.mimet.2009.10.018.
41. Heap JT, Pennington OJ, Cartman ST, Carter GP, Minton NP. 2007. The ClosTron: a universal gene knock-out system for the genus Clostridium. J. Microbiol. Methods 70:452-464. http://dx.doi.org/10.1016/j.mimet.2007.05.021.
42. Kim L, Mogk A, Schumann W. 1996. A xylose-inducible Bacillus subtilis integration vector and its application. Gene 181:71-76. http://dx.doi.org/10.1016/S0378-1119(96)00466-0.
43. McBride SM, Sonenshein AL. 2011. Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infect. Immun. 79:167-176. http://dx.doi.org/10.1128/IAI.00731-10.
44. Fagan RP, Fairweather NF. 2011. Clostridium difficile has two parallel and essential Sec secretion systems. J. Biol. Chem. 286:27483-27493. http://dx.doi.org/10.1074/jbc.M111.263889.
45. Sambol SP, Tang JK, Merrigan MM, Johnson S, Gerding DN. 2001. Infection of hamsters with epidemiologically important strains of Clostridium difficile. J. Infect. Dis. 183:1760-1766. http://dx.doi.org/10.1086/320736.
46. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481. http://dx.doi.org/10.1080/01621459.1958.10501452.
47. McPherson DC, Popham DL. 2003. Peptidoglycan synthesis in the absence of class A penicillin-binding proteins in Bacillus subtilis. J. Bacteriol. 185:1423-1431. http://dx.doi.org/10.1128/JB.185.4.1423-1431.2003.
48. Peltier J, Courtin P, El Meouche I, Lemée L, Chapot-Chartier M-P, Pons J-L. 2011. Clostridium difficile has an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-3 cross-links. J. Biol. Chem. 286:29053-29062. http://dx.doi.org/10.1074/jbc.M111.259150.
49. Hayashi K, October R, Spectronic L, Division B. 1975. A rapid determination of sodium dodecyl sulfate with methylene blue. Anal. Biochem. 506:503-506.
50. Zhang G, Darius S, Smith SR, Ritchie SJ. 2006. In vitro inhibitory effect of hen egg white lysozyme on Clostridium perfringens type A associated with broiler necrotic enteritis and its alpha-toxin production. Lett. Appl. Microbiol. 42:138-143. http://dx.doi.org/10.1111/j.1472-765X.2005.01812.x.
51. Trieu-Cuot P, Carlier C, Poyart-Salmeron C, Courvalin P. 1991. Shuttle vectors containing a multiple cloning site and a lacZα gene for conjugal transfer of DNA from Escherichia coli to Gram-positive bacteria. Gene 102:99-104. http://dx.doi.org/10.1016/0378-1119(91)90546-N.